search
Back to results

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

Primary Purpose

Spinal Cord Injury

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CSFD and elevation of MAP
Maintenance of MAP
Sponsored by
St. Joseph's Hospital and Medical Center, Phoenix
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injury focused on measuring spinal cord injury (SCI)

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 18-75 years inclusive;
  • Diagnosis of acute SCI;
  • Injury is less than 24 hours old;
  • ISNCSCI Impairment Scale Grade "A," "B" or "C" based upon first ISNCSCI evaluation after arrival to the hospital;
  • Neurological level of injury between C4-C8 based upon first ISNCSCI evaluation after arrival to the hospital;
  • Women of childbearing potential must have a negative serum β-hCG pregnancy test or a negative urine pregnancy test;
  • Patient is willing to participate in the study;
  • Informed consent document signed by patient or witnessed informed consent document;
  • No contraindications for study treatment(s);
  • Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (includes patients who are on a ventilator).

Exclusion Criteria:

  • Injury arising from penetrating mechanism;
  • Significant concomitant head injury defined by a Glasgow Coma Scale (GCS) score < 14 with a clinically significant abnormality on a head CT (head CT required only for patients suspected to have a brain injury at the discretion of the investigator);
  • Pre-existing neurologic or mental disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with- hallucinations and/or delusions or schizophrenia);
  • Prior history of SCI;
  • Recent history (less than 1 year) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation, in the opinion of the investigator;
  • Is a prisoner;
  • Participation in another clinical trial within the past 30 days;
  • Acquired immune deficiency syndrome (AIDS) or AIDS-related complex;
  • Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated. Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study.

Sites / Locations

  • University of Alabama School of Medicine Department of Neurosurgery
  • Barrow Neurological Institute St. Joseph's Hospital and Medical Center
  • University of Arizona Department of Surgery Division of Neurosurgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CSFD with elevation of MAP

Maintenance of MAP

Arm Description

Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.

Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.

Outcomes

Primary Outcome Measures

Change in ITP
ITP will be measured in both groups every hour for the duration of study treatment for a total of 121 measurements consisting of one pre-treatment measurement (time 0 hours) and 120 measurements during the treatment (time 1-120 hours).
Change in International Standards for Classification of Spinal Cord Injury Motor Score (ISNCSCI, formerly ASIA)
ISNCSCI Motor Score will be obtained at hospital arrival (baseline), 72 hours post-injury, 84 days and 180 days post-treatment. The primary endpoint is difference between the Motor Score at 180 days and baseline.

Secondary Outcome Measures

ISNCSCI Grade
ISNCSCI Sensory Scores
ISNCSCI Upper Extremity Motor Score
ISNCSCI Lower Extremity Motor Score
Spinal Cord Independence Measure (SCIM)
Pain level per patient report
Using a numeric pain rating scale, subjects will indicate level of pain at time measure occurs

Full Information

First Posted
July 8, 2015
Last Updated
November 25, 2019
Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Collaborators
University of Miami
search

1. Study Identification

Unique Protocol Identification Number
NCT02495545
Brief Title
Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury
Official Title
A Multi-Center, Randomized, Controlled, Trial of Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
October 25, 2019 (Actual)
Study Completion Date
October 25, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Collaborators
University of Miami

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this Phase IIB randomized controlled trial is to evaluate the safety and efficacy of CSFD and to provide a preliminary clinical efficacy evaluation of the combination of CSFD and elevation of mean arterial pressure (MAP) in patients with acute spinal cord injury (SCI). The objectives of the trial are to evaluate (i) efficacy of reducing intrathecal pressure (ITP) by CSFD in patients with acute SCI; (ii) preliminary efficacy of combination of CSFD and elevation of MAP compared to elevation of MAP alone in improving neurologic motor outcomes in patients with acute SCI; and, (iii) safety of intensive CSFD in acute SCI patients.
Detailed Description
Acute spinal cord injury (SCI) affects 10,000-14,000 persons per year in the United States (Burke, Linden et al. 2001). There are 150,000-300,000 persons living with significant disabilities from SCI at any given time (Bernhard, Gries et al. 2005). The average age of incident cases of SCI is 47 years and about 78% of the cases are males (DeVivo and Chen 2011). Estimates of the lifetime costs to care for someone with a SCI range from $325,000 to $1.35 million and the yearly cost to society reaches $8 billion (Sekhon and Fehlings 2001). With better long term care technologies, these costs are expected to continue to rise. Although there have been significant advances in accessibility for people with disabilities, the goal of medical science is to overcome the physiological barriers imposed by the injury itself and allow these individuals to regain their pre-injury level of neurological function (Rowland, Hawryluk et al. 2008). The injury to the spinal cord occurs in two phases. The first phase is the primary physical damage due to the impact energy of the compressive nature of the injury. The damage can be very complex with shearing of the axons, destruction of the cell bodies and disruption of the microvasculature at the site of injury. The secondary phase of the injury begins soon after the primary injury has occurred and can be influenced by many factors such as hypoxia, hypotension, and the extent of the primary injury. Spinal cord ischemia post-injury causes a significant increase in cell death and more significant neurological disability. Limiting tissue hypoperfusion post-injury can decrease the amount of cell death and axonal damage. Lumbar cerebrospinal fluid drainage (CSFD) together with increased mean arterial blood pressure (MAP) in the immediate post-injury period can reduce spinal cord tissue hypoperfusion. By reducing spinal cord hypoperfusion through elevation of MAP, less cell death and axonal damage will occur, leading to an improvement in neurological function. The feasibility of CSFD as a means for reducing the intrathecal pressure (ITP) in patients with acute SCI has been demonstrated in a small randomized controlled trial by Kwon et al (Kwon, Curt et al. 2009). The limitations were a small sample size, broad inclusion criteria, lack of statistical power calculation and restricted drainage regimen (maximum 10 mL per hour).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injury
Keywords
spinal cord injury (SCI)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CSFD with elevation of MAP
Arm Type
Experimental
Arm Description
Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
Arm Title
Maintenance of MAP
Arm Type
Active Comparator
Arm Description
Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
Intervention Type
Procedure
Intervention Name(s)
CSFD and elevation of MAP
Intervention Description
Lumbar drain placement with CSFD with elevation of MAP
Intervention Type
Procedure
Intervention Name(s)
Maintenance of MAP
Intervention Description
Lumbar drain placement without CSFD and with maintenance of MAP
Primary Outcome Measure Information:
Title
Change in ITP
Description
ITP will be measured in both groups every hour for the duration of study treatment for a total of 121 measurements consisting of one pre-treatment measurement (time 0 hours) and 120 measurements during the treatment (time 1-120 hours).
Time Frame
120 hours
Title
Change in International Standards for Classification of Spinal Cord Injury Motor Score (ISNCSCI, formerly ASIA)
Description
ISNCSCI Motor Score will be obtained at hospital arrival (baseline), 72 hours post-injury, 84 days and 180 days post-treatment. The primary endpoint is difference between the Motor Score at 180 days and baseline.
Time Frame
180 days
Secondary Outcome Measure Information:
Title
ISNCSCI Grade
Time Frame
Change in ISNCSCI grade between 180 days and baseline
Title
ISNCSCI Sensory Scores
Time Frame
Change in ISNCSCI Sensory Scores (Light Touch and Pin Prick) between 180 days and baseline
Title
ISNCSCI Upper Extremity Motor Score
Time Frame
Change in ISNCSCI Upper Extremity Motor Score between 180 days and baseline
Title
ISNCSCI Lower Extremity Motor Score
Time Frame
Change in ISNCSCI Lower Extremity Motor Score between 180 days and baseline
Title
Spinal Cord Independence Measure (SCIM)
Time Frame
Spinal Cord Independence Measure (SCIM) at 180 days
Title
Pain level per patient report
Description
Using a numeric pain rating scale, subjects will indicate level of pain at time measure occurs
Time Frame
Pain Numeric Rating Scale (NRS) at 180 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18-75 years inclusive; Diagnosis of acute SCI; Injury is less than 24 hours old; ISNCSCI Impairment Scale Grade "A," "B" or "C" based upon first ISNCSCI evaluation after arrival to the hospital; Neurological level of injury between C4-C8 based upon first ISNCSCI evaluation after arrival to the hospital; Women of childbearing potential must have a negative serum β-hCG pregnancy test or a negative urine pregnancy test; Patient is willing to participate in the study; Informed consent document signed by patient or witnessed informed consent document; No contraindications for study treatment(s); Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (includes patients who are on a ventilator). Exclusion Criteria: Injury arising from penetrating mechanism; Significant concomitant head injury defined by a Glasgow Coma Scale (GCS) score < 14 with a clinically significant abnormality on a head CT (head CT required only for patients suspected to have a brain injury at the discretion of the investigator); Pre-existing neurologic or mental disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with- hallucinations and/or delusions or schizophrenia); Prior history of SCI; Recent history (less than 1 year) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation, in the opinion of the investigator; Is a prisoner; Participation in another clinical trial within the past 30 days; Acquired immune deficiency syndrome (AIDS) or AIDS-related complex; Active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated. Patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicholas Theodore, MD
Organizational Affiliation
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama School of Medicine Department of Neurosurgery
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-3410
Country
United States
Facility Name
Barrow Neurological Institute St. Joseph's Hospital and Medical Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
University of Arizona Department of Surgery Division of Neurosurgery
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724-5070
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
10232536
Citation
Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery. 1999 May;44(5):1027-39; discussion 1039-40. doi: 10.1097/00006123-199905000-00052.
Results Reference
background
PubMed Identifier
15950358
Citation
Bernhard M, Gries A, Kremer P, Bottiger BW. Spinal cord injury (SCI)--prehospital management. Resuscitation. 2005 Aug;66(2):127-39. doi: 10.1016/j.resuscitation.2005.03.005.
Results Reference
background
PubMed Identifier
15561411
Citation
Brown PD, Davies SL, Speake T, Millar ID. Molecular mechanisms of cerebrospinal fluid production. Neuroscience. 2004;129(4):957-70. doi: 10.1016/j.neuroscience.2004.07.003.
Results Reference
background
PubMed Identifier
11438844
Citation
Burke DA, Linden RD, Zhang YP, Maiste AC, Shields CB. Incidence rates and populations at risk for spinal cord injury: A regional study. Spinal Cord. 2001 May;39(5):274-8. doi: 10.1038/sj.sc.3101158.
Results Reference
background
PubMed Identifier
20030558
Citation
Casha S, Christie S. A systematic review of intensive cardiopulmonary management after spinal cord injury. J Neurotrauma. 2011 Aug;28(8):1479-95. doi: 10.1089/neu.2009.1156. Epub 2010 Apr 8.
Results Reference
background
PubMed Identifier
11932655
Citation
Coselli JS, LeMaire SA, Koksoy C, Schmittling ZC, Curling PE. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. J Vasc Surg. 2002 Apr;35(4):631-9. doi: 10.1067/mva.2002.122024.
Results Reference
background
PubMed Identifier
21353817
Citation
DeVivo MJ, Chen Y. Trends in new injuries, prevalent cases, and aging with spinal cord injury. Arch Phys Med Rehabil. 2011 Mar;92(3):332-8. doi: 10.1016/j.apmr.2010.08.031.
Results Reference
background
PubMed Identifier
4682352
Citation
Dohrmann GJ, Wick KM, Bucy PC. Spinal cord blood flow patterns in experimental traumatic paraplegia. J Neurosurg. 1973 Jan;38(1):52-8. doi: 10.3171/jns.1973.38.1.0052. No abstract available.
Results Reference
background
PubMed Identifier
2471626
Citation
Fehlings MG, Tator CH, Linden RD. The relationships among the severity of spinal cord injury, motor and somatosensory evoked potentials and spinal cord blood flow. Electroencephalogr Clin Neurophysiol. 1989 Jul-Aug;74(4):241-59. doi: 10.1016/0168-5597(89)90055-5.
Results Reference
background
PubMed Identifier
8410254
Citation
Francel PC, Long BA, Malik JM, Tribble C, Jane JA, Kron IL. Limiting ischemic spinal cord injury using a free radical scavenger 21-aminosteroid and/or cerebrospinal fluid drainage. J Neurosurg. 1993 Nov;79(5):742-51. doi: 10.3171/jns.1993.79.5.0742.
Results Reference
background
PubMed Identifier
2922776
Citation
Guha A, Tator CH, Rochon J. Spinal cord blood flow and systemic blood pressure after experimental spinal cord injury in rats. Stroke. 1989 Mar;20(3):372-7. doi: 10.1161/01.str.20.3.372.
Results Reference
background
PubMed Identifier
23417174
Citation
Hadley MN, Walters BC. Introduction to the Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries. Neurosurgery. 2013 Mar;72 Suppl 2:5-16. doi: 10.1227/NEU.0b013e3182773549. No abstract available.
Results Reference
background
PubMed Identifier
12506565
Citation
Hadley MN, Walters BC, Grabb PA, Oyesiku NM, Przybylski GJ, Resnick DK, Ryken TC, Mielke DH. Guidelines for the management of acute cervical spine and spinal cord injuries. Clin Neurosurg. 2002;49:407-98. No abstract available.
Results Reference
background
PubMed Identifier
3810718
Citation
Hickey R, Albin MS, Bunegin L, Gelineau J. Autoregulation of spinal cord blood flow: is the cord a microcosm of the brain? Stroke. 1986 Nov-Dec;17(6):1183-9. doi: 10.1161/01.str.17.6.1183.
Results Reference
background
PubMed Identifier
18980472
Citation
Horn EM, Theodore N, Assina R, Spetzler RF, Sonntag VK, Preul MC. The effects of intrathecal hypotension on tissue perfusion and pathophysiological outcome after acute spinal cord injury. Neurosurg Focus. 2008;25(5):E12. doi: 10.3171/FOC.2008.25.11.E12.
Results Reference
background
PubMed Identifier
5005114
Citation
Kindt GW. Autoregulation of spinal cord blood flow. Eur Neurol. 1971-1972;6(1):19-23. doi: 10.1159/000114459. No abstract available.
Results Reference
background
PubMed Identifier
810290
Citation
Kobrine AI, Doyle TF, Martins AN. Autoregulation of spinal cord blood flow. Clin Neurosurg. 1975;22:573-81. doi: 10.1093/neurosurgery/22.cn_suppl_1.573.
Results Reference
background
PubMed Identifier
409084
Citation
Kobrine AI, Evans DE, Rizzoli HV. The role of the sympathetic nervous system in spinal cord autoregulation. Acta Neurol Scand Suppl. 1977;64:54-5. No abstract available.
Results Reference
background
PubMed Identifier
19320576
Citation
Kwon BK, Curt A, Belanger LM, Bernardo A, Chan D, Markez JA, Gorelik S, Slobogean GP, Umedaly H, Giffin M, Nikolakis MA, Street J, Boyd MC, Paquette S, Fisher CG, Dvorak MF. Intrathecal pressure monitoring and cerebrospinal fluid drainage in acute spinal cord injury: a prospective randomized trial. J Neurosurg Spine. 2009 Mar;10(3):181-93. doi: 10.3171/2008.10.SPINE08217.
Results Reference
background
PubMed Identifier
21663407
Citation
Martirosyan NL, Feuerstein JS, Theodore N, Cavalcanti DD, Spetzler RF, Preul MC. Blood supply and vascular reactivity of the spinal cord under normal and pathological conditions. J Neurosurg Spine. 2011 Sep;15(3):238-51. doi: 10.3171/2011.4.SPINE10543. Epub 2011 Jun 10.
Results Reference
background
PubMed Identifier
11425944
Citation
Mokri B. The Monro-Kellie hypothesis: applications in CSF volume depletion. Neurology. 2001 Jun 26;56(12):1746-8. doi: 10.1212/wnl.56.12.1746.
Results Reference
background
PubMed Identifier
16224086
Citation
Palesch YY, Tilley BC, Sackett DL, Johnston KC, Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov;36(11):2410-4. doi: 10.1161/01.STR.0000185718.26377.07. Epub 2005 Oct 13.
Results Reference
background
PubMed Identifier
2335835
Citation
Piano G, Gewertz BL. Mechanism of increased cerebrospinal fluid pressure with thoracic aortic occlusion. J Vasc Surg. 1990 May;11(5):695-701. doi: 10.1067/mva.1990.19358.
Results Reference
background
PubMed Identifier
19935758
Citation
Ploumis A, Yadlapalli N, Fehlings MG, Kwon BK, Vaccaro AR. A systematic review of the evidence supporting a role for vasopressor support in acute SCI. Spinal Cord. 2010 May;48(5):356-62. doi: 10.1038/sc.2009.150. Epub 2009 Nov 24.
Results Reference
background
PubMed Identifier
18980476
Citation
Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008;25(5):E2. doi: 10.3171/FOC.2008.25.11.E2.
Results Reference
background
PubMed Identifier
21418571
Citation
Royston P, Barthel FM, Parmar MK, Choodari-Oskooei B, Isham V. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials. 2011 Mar 18;12:81. doi: 10.1186/1745-6215-12-81.
Results Reference
background
PubMed Identifier
23417181
Citation
Ryken TC, Hurlbert RJ, Hadley MN, Aarabi B, Dhall SS, Gelb DE, Rozzelle CJ, Theodore N, Walters BC. The acute cardiopulmonary management of patients with cervical spinal cord injuries. Neurosurgery. 2013 Mar;72 Suppl 2:84-92. doi: 10.1227/NEU.0b013e318276ee16. No abstract available.
Results Reference
background
PubMed Identifier
11805601
Citation
Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976). 2001 Dec 15;26(24 Suppl):S2-12. doi: 10.1097/00007632-200112151-00002.
Results Reference
background
PubMed Identifier
430132
Citation
Senter HJ, Venes JL. Loss of autoregulation and posttraumatic ischemia following experimental spinal cord trauma. J Neurosurg. 1979 Feb;50(2):198-206. doi: 10.3171/jns.1979.50.2.0198.
Results Reference
background
PubMed Identifier
624973
Citation
Smith AJ, McCreery DB, Bloedel JR, Chou SN. Hyperemia, CO2 responsiveness, and autoregulation in the white matter following experimental spinal cord injury. J Neurosurg. 1978 Feb;48(2):239-51. doi: 10.3171/jns.1978.48.2.0239.
Results Reference
background
PubMed Identifier
8433431
Citation
Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg. 1993 Feb;17(2):357-68; discussion 368-70.
Results Reference
background
PubMed Identifier
22978443
Citation
Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Green C, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann G, James ND. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012 Sep 15;13:168. doi: 10.1186/1745-6215-13-168.
Results Reference
background
PubMed Identifier
6667588
Citation
Tator CH. Spine-spinal cord relationships in spinal cord trauma. Clin Neurosurg. 1983;30:479-94. doi: 10.1093/neurosurgery/30.cn_suppl_1.479. No abstract available.
Results Reference
background
PubMed Identifier
2045903
Citation
Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg. 1991 Jul;75(1):15-26. doi: 10.3171/jns.1991.75.1.0015.
Results Reference
background
PubMed Identifier
23417175
Citation
Walters BC. Methodology of the Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries. Neurosurgery. 2013 Mar;72 Suppl 2:17-21. doi: 10.1227/NEU.0b013e318276ed9a. No abstract available.
Results Reference
background
PubMed Identifier
23839357
Citation
Walters BC, Hadley MN, Hurlbert RJ, Aarabi B, Dhall SS, Gelb DE, Harrigan MR, Rozelle CJ, Ryken TC, Theodore N; American Association of Neurological Surgeons; Congress of Neurological Surgeons. Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update. Neurosurgery. 2013 Aug;60(CN_suppl_1):82-91. doi: 10.1227/01.neu.0000430319.32247.7f. No abstract available.
Results Reference
background

Learn more about this trial

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

We'll reach out to this number within 24 hrs